Ahmad Masri1, Ahmed M Altibi2, Sebhat Erqou3, Mohammad A Zmaili2, Ala Saleh2, Raed Al-Adham4, Karam Ayoub5, Moaaz Baghal2, Laith Alkukhun2, Amr F Barakat2, Sandeep Jain2, Samir Saba2, Evan Adelstein6. 1. Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. Electronic address: masria@upmc.edu. 2. Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 3. Department of Medicine, Providence VA Medical Center and Alpert Medical School of Brown University, Providence, Rhode Island. 4. Department of Medicine, University of Arizona, Phoenix, Arizona. 5. Division of Cardiology, Department of Medicine, University of Kentucky, Lexington, Kentucky. 6. Division of Cardiology, Albany Medical College, Albany, New York.
Abstract
OBJECTIVES: This study sought to synthesize the available evidence on the use of the wearable cardioverter-defibrillator (WCD). BACKGROUND: Observational WCD studies for the prevention of sudden cardiac death have provided conflicting data. The VEST (Vest Prevention of Early Sudden Death) trial was the first randomized controlled trial (RCT) showing no reduction in sudden cardiac death as compared to medical therapy only. METHODS: We searched PubMed, EMBASE, and Google Scholar for studies reporting on the outcomes of patients wearing WCDs from January 1, 2001, through March 20, 2018. Rates of appropriate and inappropriate WCD therapies were pooled. Estimates were derived using DerSimonian and Laird's method. RESULTS: Twenty-eight studies were included (N = 33,242; 27 observational, 1 RCT-WCD arm). The incidence of appropriate WCD therapy was 5 per 100 persons over 3 months (95% confidence interval [CI]: 3.0 to 6.0, I2 = 93%). In studies on ischemic cardiomyopathy, the appropriate WCD therapy incidence was lower in the VEST trial (1 per 100 persons over 3 months; 95% CI: 1.0 to 2.0) as compared with observational studies (11 per 100 persons over 3 months; 95% CI: 11.0 to 20.0; I2 = 93%). The incidence of inappropriate therapy was 2 per 100 persons over 3 months (95% CI: 1.0 to 3.0; I2 = 93%). Mortality while wearing WCD was rare at 0.7 per 100 persons over 3 months (95% CI: 0.3 to 1.7; I2 = 94%). CONCLUSIONS: The rate of appropriately treated WCD patients over 3 months of follow-up was substantial; higher in-observational studies as compared with the VEST trial. There was significant heterogeneity. More RCTs are needed to justify continued use of WCD in primary prevention.
OBJECTIVES: This study sought to synthesize the available evidence on the use of the wearable cardioverter-defibrillator (WCD). BACKGROUND: Observational WCD studies for the prevention of sudden cardiac death have provided conflicting data. The VEST (Vest Prevention of Early Sudden Death) trial was the first randomized controlled trial (RCT) showing no reduction in sudden cardiac death as compared to medical therapy only. METHODS: We searched PubMed, EMBASE, and Google Scholar for studies reporting on the outcomes of patients wearing WCDs from January 1, 2001, through March 20, 2018. Rates of appropriate and inappropriate WCD therapies were pooled. Estimates were derived using DerSimonian and Laird's method. RESULTS: Twenty-eight studies were included (N = 33,242; 27 observational, 1 RCT-WCD arm). The incidence of appropriate WCD therapy was 5 per 100 persons over 3 months (95% confidence interval [CI]: 3.0 to 6.0, I2 = 93%). In studies on ischemic cardiomyopathy, the appropriate WCD therapy incidence was lower in the VEST trial (1 per 100 persons over 3 months; 95% CI: 1.0 to 2.0) as compared with observational studies (11 per 100 persons over 3 months; 95% CI: 11.0 to 20.0; I2 = 93%). The incidence of inappropriate therapy was 2 per 100 persons over 3 months (95% CI: 1.0 to 3.0; I2 = 93%). Mortality while wearing WCD was rare at 0.7 per 100 persons over 3 months (95% CI: 0.3 to 1.7; I2 = 94%). CONCLUSIONS: The rate of appropriately treated WCD patients over 3 months of follow-up was substantial; higher in-observational studies as compared with the VEST trial. There was significant heterogeneity. More RCTs are needed to justify continued use of WCD in primary prevention.
Authors: Thomas Beiert; Robert Malotki; Natalie Kraemer; Florian Stöckigt; Markus Linhart; Georg Nickenig; Jan W Schrickel; René P Andrié Journal: J Electrocardiol Date: 2017-04-28 Impact factor: 1.438
Authors: Lars Køber; Jens J Thune; Jens C Nielsen; Jens Haarbo; Lars Videbæk; Eva Korup; Gunnar Jensen; Per Hildebrandt; Flemming H Steffensen; Niels E Bruun; Hans Eiskjær; Axel Brandes; Anna M Thøgersen; Finn Gustafsson; Kenneth Egstrup; Regitze Videbæk; Christian Hassager; Jesper H Svendsen; Dan E Høfsten; Christian Torp-Pedersen; Steen Pehrson Journal: N Engl J Med Date: 2016-08-27 Impact factor: 91.245
Authors: Madhab Lamichhane; Joseph C Gardiner; Nicole R Bianco; Steven J Szymkiewicz; Ranjan K Thakur Journal: J Interv Card Electrophysiol Date: 2016-10-17 Impact factor: 1.900
Authors: Jeffrey E Olgin; Mark J Pletcher; Eric Vittinghoff; Jerzy Wranicz; Rajesh Malik; Daniel P Morin; Steven Zweibel; Alfred E Buxton; Claude S Elayi; Eugene H Chung; Eric Rashba; Martin Borggrefe; Trisha F Hue; Carol Maguire; Feng Lin; Joel A Simon; Stephen Hulley; Byron K Lee Journal: N Engl J Med Date: 2018-09-27 Impact factor: 91.245
Authors: Andrew E Epstein; William T Abraham; Nicole R Bianco; Karl B Kern; Michael Mirro; Sunil V Rao; Edward K Rhee; Scott D Solomon; Steven J Szymkiewicz Journal: J Am Coll Cardiol Date: 2013-07-31 Impact factor: 24.094
Authors: Irene Kirolos; David Jones; Kirstin Hesterberg; Charles Yarn; Rami N Khouzam; Yehoshua C Levine Journal: Curr Treat Options Cardiovasc Med Date: 2019-08-08
Authors: Andreas Hain; Nikolai Busch; Said Elias Waezsada; Julie Hutter; Patrick Kahle; Malte Kuniss; Thomas Neumann; Tsyuoshi Masuda; Horst O Esser; Christian Hamm; Johannes Sperzel Journal: J Clin Med Date: 2022-05-20 Impact factor: 4.964
Authors: Christian Kuehn; Stefan Ruemke; Philipp Rellecke; Artur Lichtenberg; Dominik Joskowiak; Christian Hagl; Mohamed Hassan; Rainer G Leyh; Stefan Erler; Jens Garbade; Sandra Eifert; Philippe Grieshaber; Andreas Boening; Torsten Doenst; Ilia Velichkov; Tomas Madej; Michael Knaut; Andreas Hain; Heiko Burger Journal: Eur J Cardiothorac Surg Date: 2022-05-02 Impact factor: 4.534